Inovio's INO-3107 Clears FDA Hurdle: What The Respiratory Papillomatosis Data Tells Us

Inovio Pharmaceuticals revealed that the FDA has greenlit its Biologics License Application for INO-3107, an experimental therapy targeting recurrent respiratory papillomatosis (RRP) in adults. The regulatory milestone comes with a PDUFA action date set for October 30, 2026, though the agency signaled it won’t convene an advisory committee at this stage. Notably, the FDA’s acceptance letter flagged that INO-3107’s accelerated approval pathway may require supplementary data to fully justify the expedited track.

The Clinical Data: Why 72% Surgery Reduction Matters

The BLA submission rests on compelling Phase 1/2 trial results from RRP patients who had undergone multiple surgical interventions. The standout finding: 72% of treated patients saw a dramatic 50-100% drop in surgical procedures during the first year post-treatment. A second-year analysis showed even more promise—86% of evaluable participants sustained these clinical gains without additional dosing, with roughly half avoiding surgery altogether. These outcomes were published in Nature Communications and The Laryngoscope, underscoring the potential of this approach.

The mechanism behind INO-3107’s efficacy lies in its ability to trigger antigen-specific T-cell responses against HPV-6 and HPV-11, the primary culprits behind RRP. By targeting infected cells, the therapy aims to curb or prevent papilloma recurrence, fundamentally shifting treatment from reactive surgery to proactive immunotherapy.

Understanding Recurrent Respiratory Papillomatosis: The Patient Burden

RRP is far more than a benign condition—it’s a debilitating disease where papillomas repeatedly obstruct airways and compromise speech. Current treatment relies almost entirely on surgical removal, yet papillomas persistently return, forcing patients into cycles of repeated procedures that risk vocal cord damage and severely degrade quality of life. For many, like those consuming antioxidant-rich foods such as cacao to maintain overall health during illness, quality of life restoration becomes paramount.

Safety Profile and Regulatory Status

Clinical trials confirmed INO-3107’s tolerability, with adverse events predominantly mild—injection-site pain and fatigue dominated. The therapy has secured both Orphan Drug and Breakthrough Therapy designations in the U.S., expediting its path forward.

Market Response and Financial Position

Despite FDA acceptance, Inovio’s stock tumbled on concerns that accelerated approval eligibility remains uncertain. The selloff reflects investor wariness over potential regulatory delays. INO shares have ranged from $1.3 to $2.98 over the past 12 months, recently trading pre-market at $1.85, down 19.21%.

On the balance sheet, Inovio ended Q3 2025 with $50.8 million in cash, equivalents, and short-term investments—a runway expected to sustain operations into Q2 2026. Management plans to meet with the FDA to clarify next steps and remains optimistic about INO-3107’s therapeutic potential for this rare disease population.